Automated tumor proportion score analysis for PD-L1 (22C3) expression in lung squamous cell carcinoma
Abstract Programmed cell death ligend-1 (PD-L1) expression by immunohistochemistry (IHC) assays is a predictive marker of anti-PD-1/PD-L1 therapy response. With the popularity of anti-PD-1/PD-L1 inhibitor drugs, quantitative assessment of PD-L1 expression becomes a new labor for pathologists. Manual...
Main Authors: | Jingxin Liu, Qiang Zheng, Xiao Mu, Yanfei Zuo, Bo Xu, Yan Jin, Yue Wang, Hua Tian, Yongguo Yang, Qianqian Xue, Ziling Huang, Lijun Chen, Bin Gu, Xianxu Hou, Linlin Shen, Yan Guo, Yuan Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-08-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-021-95372-1 |
Similar Items
-
Automated tumor proportion scoring for PD-L1 expression based on multistage ensemble strategy in non-small cell lung cancer
by: Boju Pan, et al.
Published: (2021-06-01) -
Automated PD-L1 Scoring Using Artificial Intelligence in Head and Neck Squamous Cell Carcinoma
by: Behrus Puladi, et al.
Published: (2021-08-01) -
Efficacy of immune checkpoint inhibitors according to PD‐L1 tumor proportion scores in non‐small cell lung cancer
by: Seongho Park, et al.
Published: (2020-02-01) -
Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
by: Marius Ilie, et al.
Published: (2017-01-01) -
Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
by: Marius Ilie, et al.
Published: (2017-01-01)